IP Library › Granted Patent US 12,281,169
Granted Patent B2
US 12,281,169 · App. 17/854,904 · Granted Apr 22, 2025

Antibodies that bind to OX40 and their uses

Inventors: Antoine Attinger (La Chaux-de Fonds, CH); Stanislas Blein (La Chaux-de-Fonds, CH); Jonathan Albert Back (La Chaux-de-Fonds, CH); Rami Lissilaa (La Chaux-de-Fonds, CH); Samuel Hou (La Chaux-de-Fonds, CH)
Assignee: Ichnos Sciences SA
C07K16/2878A61K39/3955A61K45/06A61K2039/505C07K2317/24C07K2317/33C07K2317/34C07K2317/41C07K2317/52C07K2317/53C07K2317/73C07K2317/732C07K2317/76C07K2317/92C07K2317/94G01N2333/70578
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,169
App. No.
17/854,904
Granted
Apr 22, 2025
Kind
B2
Abstract

The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

Claims (36)

1. An antagonistic antibody or fragment thereof that binds to human OX40, wherein said antibody or fragment thereof comprises:

a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and

a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

2. The manufacture antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof is a murine antibody, chimeric antibody or a humanized antibody.

3. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof is a humanized antibody.

4. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 7.

5. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a non-CDR region of a heavy chain variable region sequence which is at least 80% identical to the non-CDR region of the heavy chain variable region sequence of SEQ ID NO: 7.

6. The antibody or fragment thereof of claim 1 , wherein the heavy chain sequence comprises a non-CDR region which is at least 80% identical to the non-CDR region of the heavy chain variable region sequence of the heavy chain sequence selected from the group consisting of SEQ ID NOS: 35, 36, 37 and 38.

7. The antibody or fragment thereof of claim 6 , wherein the antibody or fragment thereof comprises a heavy chain sequence comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 35, 36, 37 and 38.

8. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable region sequence comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 58, 59, 79 and 80.

9. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a non-CDR region of a heavy chain variable region sequence which is at least 80% identical to the non-CDR region of the heavy chain variable region sequence selected from the group consisting of SEQ ID NOS: 58, 59, 79 and 80.

10. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable framework region that is the product of a human gene selected from the group consisting of IGHV2-70*10 (SEQ ID NO: 19), IGHV2-70*01 (SEQ ID NO: 20), IGHV2-70*13 (SEQ ID NO: 21), IGHV2-5*09 (SEQ ID NO: 22), and IGHV2-70*11 (SEQ ID NO: 23).

11. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable framework region that is the product of human gene IGHV2-70*10 (SEQ ID NO: 19), and wherein in the heavy chain variable framework region at least one amino acid is replaced with a corresponding amino acid from a heavy chain variable framework region of a corresponding murine antibody of SEQ ID NO: 7 or wherein the antibody or fragment thereof comprises a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 32 and wherein in the heavy chain variable framework region at least one amino acid is replaced with a corresponding amino acid from the heavy chain variable framework region of the corresponding murine antibody of SEQ ID NO: 7.

12. The antibody or fragment thereof of claim 11 , wherein the amino acid replacement is at an amino acid position selected from the group consisting of 23, 35, 48, 50, 60 and 62, wherein the amino acid position of each group member is indicated according to the Kabat numbering.

13. The antibody or fragment thereof of claim 11 , wherein the amino acid replacement is selected from the group consisting of 23S, 35G, 48L, 50H, 60N, and 62A, wherein the amino acid position of each group member is indicated according to the Kabat numbering.

14. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 8, wherein the antibody or fragment thereof comprises a non-CDR region of a light chain variable region sequence which is at least 80% identical to the non-CDR region of the light chain variable region sequence of SEQ ID NO: 8, and/or wherein the light chain sequence comprises a non-CDR region which is at least 80% identical to the non-CDR region of the light chain variable region sequence of the light chain sequence selected from the group consisting of SEQ ID NOS: 45, 46, 47 and 49.

15. The antibody or fragment thereof of claim 14 , wherein the antibody or fragment thereof comprises a light chain sequence comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 45, 46, 47 and 49.

16. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a light chain variable region sequence comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 60, 86, 87 and 89, wherein the antibody or fragment thereof comprises a non-CDR region of a light chain variable region sequence which is at least 80% identical to the non-CDR region of the light chain variable region sequence selected from the group consisting of SEQ ID NOS: 60, 86, 87 and 89 and/or wherein the antibody or fragment thereof comprises a light chain variable framework region that is the product of a human gene selected from the group consisting of IGKV3-11*01 (SEQ ID NO: 24), IGKV1-39*01 (SEQ ID NO: 25), IGKV1D-39*01 (SEQ ID NO: 26), IGKV3-11*02 (SEQ ID NO: 27) and IGKV3-20*01 (SEQ ID NO: 28).

17. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a light chain variable framework region that is the product of human gene IGKV3-11*01 (SEQ ID NO: 24) and wherein in the light chain variable framework region at least one amino acid is deleted or is replaced with a corresponding amino acid from a light chain variable framework region of a corresponding murine antibody of SEQ ID NO: 8 and/or wherein the antibody or fragment thereof comprises a light chain sequence comprising the amino acid sequence of SEQ ID NO: 39 and wherein in the light chain variable framework region at least one amino acid is deleted or replaced with a corresponding amino acid from the light chain variable framework region of the corresponding murine antibody of SEQ ID NO: 8.

18. The antibody or fragment thereof of claim 17 , wherein the amino acid replacement is at an amino acid position selected from the group consisting of 1, 33, 34, 46, 47, 54, 56, and 71, wherein the amino acid position of each group member is indicated according to the Kabat numbering.

19. The antibody or fragment thereof of claim 17 , wherein the amino acid replacement is selected from the group consisting of 1Q, 33M, 34H, 46P, 47W, 54L, 56S, and 71Y, wherein the amino acid position of each group member is indicated according to the Kabat numbering.

20. The antibody or fragment thereof of claim 17 , wherein the amino acid deletion is at amino acid position 31, wherein the amino acid position is indicated according to the Kabat numbering.

21. The antibody of claim 1 , wherein the antibody comprises:

(a) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO:37 and

(b) a light chain sequence comprising the amino acid sequence of SEQ ID NO:47.

22. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises:

(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:58 and

(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:60.

23. The antibody or fragment thereof of claim 1 , wherein the antibody further comprises a heavy and/or a light constant region.

24. The antibody or fragment thereof of claim 23 , wherein the heavy chain constant region is selected from the group of human immunoglobulins consisting of IGHG1, non fucosylated IGHG1, and IGHG4.

25. The antibody or fragment thereof of claim 1 , wherein the antibody is a monovalent antibody, a full length antibody, or an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, F (ab′)2, scFv, bispecific single chain Fv dimers, diabodies, triabodies and scFv genetically fused to the same or a different antibody.

26. The antibody or fragment thereof of claim 1 , wherein the antibody comprises a variant Fc region which comprises at least one amino acid modification relative to the Fc region of a parent antibody, whereas the antibody comprising the variant Fc region exhibits altered effector function compared to the parent antibody.

27. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof binds to human OX40 with an affinity (Kd) of 110 nM or less and/or the antibody has a Fab fragment thermostability temperature greater than 75° C.

28. A kit comprising an antagonistic antibody or fragment thereof that binds to human OX40, wherein said antibody or fragment thereof comprises:

a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and

a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2022
From: ATTINGER, ANTOINE; BLEIN, STANISLAS; BACK, JONATHAN ALBERT; LISSILAA, RAMI; HOU, SAMUEL
To: GLENMARK PHARMACEUTICALS S.A.
Reel/Frame 061175/0966 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2022
From: GLENMARK PHARMACEUTICALS S.A.
To: ICHNOS SCIENCES SA
Reel/Frame 061504/0010 →
Continuity (6)
Division 16298289 · Mar 11, 2019
Continuation 15348774 · Nov 10, 2016
Continuation 14222421 · Mar 21, 2014
Continuation 13545708 · Jul 10, 2012
Provisional Application 61506491 · Jul 11, 2011
Related Publication 20220411526A1 · Dec 29, 2022
References Cited (132)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5571894A · Wels et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5587458A · King et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5677425A · Bodmer et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 6121022A · Presta et al. · 2000 [cited by applicant]
US 6165745A · Ward et al. · 2000 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6180377B1 · Morgan et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6632927B2 · Adair et al. · 2003 [cited by applicant]
US 6875433B2 · Hart et al. · 2005 [cited by applicant]
US 7365167B2 · Watkins et al. · 2008 [cited by applicant]
US 7605237B2 · Stevens et al. · 2009 [cited by applicant]
US 7722876B2 · Polonelli et al. · 2010 [cited by applicant]
US 8110664B2 · Sanders et al. · 2012 [cited by applicant]
US 8748585B2 · Attinger · 2014 [cited by examiner]
US 20100136030A1 · Salah-Eddine et al. · 2010 [cited by applicant]
US 20100196359A1 · Kato et al. · 2010 [cited by applicant]
US 20100215651A1 · Blein et al. · 2010 [cited by applicant]
US 20100254978A1 · Lawson et al. · 2010 [cited by applicant]
EP 183070A2 · 1986 [cited by applicant]
EP 244234A2 · 1987 [cited by applicant]
EP 0338841A1 · 1989 [cited by applicant]
EP 402226A1 · 1990 [cited by applicant]
EP 2631246A1 · 2013 [cited by applicant]
WO WO8704462A1 · 1987 [cited by applicant]
WO WO8901036A1 · 1989 [cited by applicant]
WO WO9311161A1 · 1993 [cited by applicant]
WO WO9316185A2 · 1993 [cited by applicant]
WO WO9413804A1 · 1994 [cited by applicant]
WO WO9429351A2 · 1994 [cited by applicant]
WO WO0042072A2 · 2000 [cited by applicant]
WO WO03035835A2 · 2003 [cited by applicant]
WO WO2007062245A2 · 2007 [cited by applicant]
WO WO2008106116A2 · 2008 [cited by applicant]
WO WO2010095031A2 · 2010 [cited by applicant]
WO WO2010096418A2 · 2010 [cited by applicant]
Blazar, B.R., et al., “Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients,” Blood 101(9):3741-3748, American Society of Hematology, Un… [cited by applicant]
Compaan, D. M., and Hymowitz, S.G., “The Crystal Structure of Costimulatory OX40-OX40L Complex,” Structure 14(8):1321-1330, Cell Press, United States (2006). [cited by applicant]
Huston, J.S., et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Imal-Nishiya, H., et al., “Double knockdown of alpha 1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antib… [cited by applicant]
International Search Report for International Application No. PCT/IB2012/053502, European Patent Office, Netherlands, mailed Sep. 10, 2012. [cited by applicant]
Kasai, Y., et al., “Molecular cloning of murine monoclonal anti-idiotypic Fab,” J. Immunological Methods 155(1):77-89, Elsevier Science Publishers B.V., Netherlands (1992). [cited by applicant]
Kotani, A., et al., “Correlation of peripheral blood OX40+ (CD134+) T-cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation,” Blood 98:3162-3164, Ameri… [cited by applicant]
Longmore, G.D., and Schachter, H., “Product-identification and substrate-specificity studies of the GDP-L-fucose: 2-acetamido-2-deoxy-beta-D-glucoside (FUC-Asn-linked GlcNAc) 6-alpha-L-fucosyltransferase in a Golgi-rich… [cited by applicant]
MacCallum, R.M., et al., “Antibody-antigen Interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262:732-745, Academic Press Inc., United States (1996). [cited by applicant]
O'Flaherty, E., et al., “Regulation of T-cell apoptosis: a mixed lymphocyte reaction model,” Immunology 100(3):289-299, Blackwell Science Ltd., United Kingdom (2000). [cited by applicant]
Panka, D.J., et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,” Proc. Natl. Acad. Sci. USA 85:3080-3084, National Academy of Sciences, United St… [cited by applicant]
Paterson, D., et al., “Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts,” Mol. Immunol. 24(12):1281-1290, Pergamon Press, United Kingdom (1987). [cited by applicant]
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA 79:1979-1983, National Academy of Sciences, United States (1982). [cited by applicant]
Salek-Ardakani, S., et al., “OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease,” Curr. Immunol. Rev. 2:37-53, Bentham Science Publishers B.V., United Arab Emirates (2006). [cited by applicant]
Simpson, D., “New Developments in the Prophylaxis and Treatment of Graft versus Host Disease,” Expert Opin. Pharmacother. 2(7):1109-1117, Informa Healthcare, United Kingdom (2001). [cited by applicant]
Valzasina, B., et al., “Triggering of OX40 (CD134) on CD4+CD25+ T cell blocks their inhibitory activity : a novel regulatory role for OX40 and its comparison with GITR,” Blood 105(7):2845-2851, American Society of Hemat… [cited by applicant]
Van Der Keyl, H., et al., “Disparity in the kinetics of onset of hypermutation in immunoglobulin heavy and light chains,” Immunology and Cell Biology 78(3):224-237, University of Adelaide, Australia (2000 ). [cited by applicant]
Xhaard, A., et al., “Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011,” Bull. Cancer 98(8):889-899, John Libbey Eurotext, France (Aug. 2011). [cited by applicant]
Xiaoyan, Z., et al., “Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis,” [cited by applicant]
Allen, T.M., “Ligand-targeted therapeutics in anticancer therapy,” Nat. Rev. Cancer 2:750-763, Nature Portfolio, Germany (2002). [cited by applicant]
Arnold, K., et al., “The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling,” Bioinformatics 22(2):195-201, Oxford University Press, United Kingdom (2006). [cited by applicant]
Arnon, et al., “Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy,” in [cited by applicant]
Barbas, C., et al., “Recognition of DNA by synthetic antibodies,” J. Am. Chem. Soc. 116:2161-2162, American Chemical Society, United States (1994). [cited by applicant]
Beiboer, S.H., et al., “Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent,” J. Mol. Bio… [cited by applicant]
Bensmana, M., et al., “The human immunoglobulin pseudo-gamma IGHGP gene shows no major structural defect,” Nucleic Acids Res. 16(7):3108, Oxford University Press, United Kingdom (1988). [cited by applicant]
Bird, R.E., et al., “Single-chain antigen-binding proteins,” Science 242:423-426, American Association for the Advancement of Science, United States (1988). [cited by applicant]
Bodmer, J.L., et al., “The molecular architecture of the TNF superfamily,” Trends Biochem. Sci. 27:19-26, Elsevier, Netherlands (2002). [cited by applicant]
Brennan, M., et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments,” Science 229:81-83, American Association for the Advancement of Science, United States (198… [cited by applicant]
Bromelow, K.V., et al., “Whole blood assay for assessment of the mixed lymphocyte reaction,” J. Immunol. Methods 247(1-2):1-8, Elsevier, Netherlands (2001). [cited by applicant]
Carter, P., et al., “High level [cited by applicant]
Chothia, C., and Lesk, A.M., “Canonical structures for the hypervariable regions of immunoglobulins,” J. Mol. Biol. 196:901-917, Elsevier, Netherlands (1987). [cited by applicant]
Coloma, M.J., and Morrison, S.L., “Design and production of novel tetravalent bispecific antibodies,” Nat. Biotechnol. 15(2):159-163, Nature Portfolio, Germany (1997). [cited by applicant]
Cox, J.P., et al., “A directory of human germ-line V kappa segments reveals a strong bias in their usage,” Eur. J. Immunol. 24:827-836, Wiley-VCH, Germany (1994). [cited by applicant]
Dariavach, P., et al., “Human immunoglobulin C lambda 6 gene encodes the Kern+Oz-lambda chain and C lambda 4 and C lambda 5 are pseudogenes,” Proc. Natl. Acad. Sci. USA 84(24):9074-9078, National Academy of Sciences, Un… [cited by applicant]
Dupont, B., and Hansen, J.A., “Human mixed-lymphocyte culture reaction: genetics, specificity, and biological implications,” Adv. Immunol. 23:107-202, Elsevier, Netherlands (1976). [cited by applicant]
Edelman, G.M., et al., “The covalent structure of an entire gammaG immunoglobulin molecule,” Proc. Natl. Acad. Sci. USA 63(1):78-85, National Academy of Sciences, United States (1969). [cited by applicant]
Frangione, B., et al., “Human lambda light-chain constant region gene CMor lambda: the primary structure of lambda VI Bence Jones protein Mor,” Proc. Natl. Acad. Sci. USA 82(10):3415-3419, National Academy of Sciences, … [cited by applicant]
Garber, E., and Demarest, S.J., “A broad range of Fab stabilities within a host of therapeutic IgGs,” Biochem. Biophys. Res. Commun. 355:751-757, Elsevier, Netherlands (2007). [cited by applicant]
Hall, T.A., “BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT,” Nucleic Acids. Symp. Ser. 41:95-98, Oxford Academics, United Kingdom (1999). [cited by applicant]
Hellstrom, et al ., “Antibodies for Drug Delivery” in [cited by applicant]
Holliger, P., et al., ““Diabodies”: small bivalent and bispecific antibody fragments,” Proc. Natl. Acad. Sci. USA 90:6444-6448, National Academy of Sciences, United States (1993). [cited by applicant]
Johnson, G., et al., “Kabat database and its applications: 30 years after the first variability plot,” Nucleic Acids Res. 28:214-218, Oxford University Press, United Kingdom (2000). [cited by applicant]
Kaas, Q., et al., “IG, TR and IgSF, MHC and MhcSF: what do we learn from the IMGT Colliers de Perles?” Brief. Funct. Genomic. Proteomic. 6(4):253-264, Oxford University Press, United Kingdom (2008). [cited by applicant]
Kabat, E.A., et al., [cited by applicant]
Kaufman, R.J., and Sharp, P.A., “Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene,” J. Mol. Biol. 159:601-621, Elsevier, Netherlands (1982). [cited by applicant]
Kearney, J.F., et al., “A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines,” J. Immunol. 123(4):1548-1550, American Association of … [cited by applicant]
Kim, D., et al., “Improved mammalian expression systems by manipulating transcriptional termination regions,” Biotechnol. Prog. 19(5):1620-1622, Wiley, United States (2003). [cited by applicant]
Klimka, A., et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,” Br. J. Cancer 83(2):252-260, Nature Portfolio, Germany (2000). [cited by applicant]
Koons, M.D., et al., “The replicator of the Epstein-Barr virus latent cycle origin of DNA replication, oriP, is composed of multiple functional elements,” J. Virol. 75(22):10582-10592, American Society for Microbiology,… [cited by applicant]
Lefranc, M.P., et al., “IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains,” Dev. Comp. Immunol. 29(3):185-203, Elsevier, Netherlands (2005). [cited by applicant]
Lefranc, M.P., et al., “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Res. 27(1):209-212, Oxford University Press, United Kingdom (1999). [cited by applicant]
Lefranc, M.P., et al., “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Res. 29(1):207-209, Oxford University Press, United Kingdom (2001). [cited by applicant]
Lefranc, M.P., et al., “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Res. 31(1):307-310, Oxford University Press, United Kingdom (2003). [cited by applicant]
Martin, A.C.R., et al., “Modeling antibody hypervariable loops: a combined algorithm,” Proc. Natl. Acad. Sci. USA 86:9268-9272, National Academy of Sciences, United States (1989). [cited by applicant]
Martin, A.C.R., et al., “Molecular modeling of antibody combining sites,” Methods Enzymol. 203:121-153, Elsevier, Netherlands (1991). [cited by applicant]
McCafferty, J., et al., “Phage antibodies: filamentous phage displaying antibody variable domains,” Nature 348:552-554, Nature Portfolio, Germany (1990). [cited by applicant]
Mizushima, T., et al., “Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans,” Genes Cells 16(11):1071-1080, Wiley-Blackwell, United States (2011). [cited by applicant]
Morimoto, K., et al., “Single-step purification of F(ab')2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW,” J. Bio… [cited by applicant]
Morrison, S.L., “Transfectomas provide novel chimeric antibodies,” Science 229:1202, American Association for the Advancement of Science, United States (1985). [cited by applicant]
Murphy, W.J., et al., “The huPBL-SCID mouse as a means to examine human immune function in vivo,” Semin. Immunol. 8(4):233-241, Academic Press Inc., United States (1996). [cited by applicant]
Order, S., “Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy,” in [cited by applicant]
Kreitman, R.J., “Immunotoxins in cancer therapy,” Curr. Opin. Immunol. 11:570-578, Elsevier Ltd., United Kingdom (1999). [cited by applicant]
Payne, G., “Progress in immunoconjugate cancer therapeutics,” Cancer Cell 3:207-212, Cell Press, United States (2003). [cited by applicant]
Pedersen, J.T., et al., “Antibody Modelling: Beyond Homology,” Immunomethods 1:126-136, Elsevier, Netherlands (1992). [cited by applicant]
Rader, C., et al., “A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries,” Proc. Natl. Acad. Sci. USA 95:8910-8915, National Academy of Sciences, United States (1998). [cited by applicant]
Rees, A.R., et al., “Antibody Combining Sites: Structure and Prediction,” in [cited by applicant]
Retter, I., et al., “VBASE2, an integrative V gene database,” Nucleic Acids Res. 33, Oxford University Press, United Kingdom (2005). [cited by applicant]
Ruiz, M., et al., “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Res 28(1):219-221, Oxford University Press, United Kingdom (2000). [cited by applicant]
Saito, G., et al., “Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities,” Adv. Drug Deliv. Rev. 55:199-215, Elsevier, Netherlands (2003). [cited by applicant]
Senter, P.D., and Springer, C.J., “Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates,” Adv. Drug Deliv. Rev. 53:247-264, Elsevier, Netherlands (2001). [cited by applicant]
Taylor, L., and Schwartz, H., “Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay,” J. Immunol. Methods. 255(1-2):67-72, Elsevier, Netherlands (2001). [cited by applicant]
Thorpe, “Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review,” in [cited by applicant]
Thorpe, P.E., and Ross, W.C., “The preparation and cytotoxic properties of antibody-toxin conjugates,” Immunol. Rev. 62:119-158, Begell House, United States (1982). [cited by applicant]
Tomlinson, I., and Hollinger, P., “Methods for generating multivalent and bispecific antibody fragments,” Methods Enzymol. 326:461-479, Elsevier, Netherlands (2000). [cited by applicant]
Tomlinson, I.M., et al., “The repertoire of human germline vH sequences reveals about fifty groups of VH segments with different hypervariable loops,” J. Mol. Biol. 227(3):776-798, Elsevier, Netherlands (1992). [cited by applicant]
Trail, P.A., et al., “Monoclonal antibody drug immunoconjugates for targeted treatment of cancer,” Cancer Immunol. Immunother. 52:328-337, Springer Science+Business Media, Germany (2003). [cited by applicant]
UniProt, “TNR4_HUMAN,” Accession No. P43489, accessed at https://www.uniprot.org/uniprotkb/P43489/entry, accessed on Jul. 28, 2022, 6 pages. [cited by applicant]
UniProtKB, “Q6FGS4_HUMAN,” UniProt Accession No. Q6FGS4, accessed at https://www.uniprot.org/uniprotkb/Q6FGS4/entry, accessed on Jul. 28, 2022, 1 page. [cited by applicant]
Urlaub, G., and Chasin, L.A., “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” Proc. Natl. Acad. Sci. USA 77:4216-4220, National Academy of Sciences, United States (1980). [cited by applicant]
Ward, E.S., et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
“Progress in Autoimmune Disease Research,” National Institutes of Health, The Autoimmune Diseases Coordinating Committee Report to Congress, Mar. 2005, pp. 1-125 (NIH Publication No. 05-5140). [cited by applicant]
Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. Sep. 2005;23(9):1126-36. [cited by applicant]
Holt LJ et al., Domain antibodies: proteins for therapy. Trends Biotechnol. Nov. 2003;21(11):484-90. [cited by applicant]
“Alzheimer's” Mayo Clinic. Website downloaded Jul. 27, 2021 (Year: 2021). [cited by applicant]
“Ischemia” Mayo Clinic. Website downloaded Jul. 27, 2021 (Year: 2021). [cited by applicant]
“Stroke” Mayo Clinic. Website downloaded Jul. 27, 2021 (Year: 2021). [cited by applicant]
Cited By (1)
US 12,742,015